Most Clicked StoriesMore >


MedImmune signs research deal with Sheffield University

BIO SmartBrief | Jul 24, 2015

MedImmune and the University of Sheffield agreed to a five-year collaboration to research the process of cell factory technology. Under the terms of the agreement, researchers from Sheffield will conduct studies related to cell engineering challenges, while MedImmune will provide financial support and contributions for the research. Pharmaceutical Business Review Online (07/23)


Tekmira gets new name, will focus on hepatitis B drug development

BIO SmartBrief | Jul 22, 2015

Merck, Ablynx expand collaboration on cancer drugs

BIO SmartBrief | Jul 23, 2015

Bristol-Myers' lung cancer drug gains EU approval

BIO SmartBrief | Jul 21, 2015

Valeant to purchase Amoun for $800M

BIO SmartBrief | Jul 20, 2015

Epirus signs biosimilar collaboration with Polpharma

BIO SmartBrief | Jul 20, 2015

Neurodegenerative disorder drug from AbbVie, C2N Diagnostics gains FDA orphan status

BIO SmartBrief | Jul 20, 2015

Lilly's solanezumab slows disease in some Alzheimer's patients, study finds

BIO SmartBrief | Jul 23, 2015

Drugmakers race to bring new migraine-preventing therapies to market

BIO SmartBrief | Jul 24, 2015

Tillotts Pharma completes acquisition of rights to AstraZeneca's GI drug

BIO SmartBrief | Jul 21, 2015


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the 2015 BIO Investor Forum!

BIO SmartBrief | Jul 27, 2015

FDA/Sponsor Interactions During Drug Development: Preliminary Data

BIO SmartBrief | Jul 27, 2015

Savings on environmental waste disposal services

BIO SmartBrief | Jul 24, 2015

Faster & better connections with quality R&D vendors

BIO SmartBrief | Jul 23, 2015

Registration is open for the 2015 BIO Investor Forum!

BIO SmartBrief | Jul 23, 2015




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more